Endotelix Diagnostics

Endotelix Diagnostics Sàrl, founded in 2019, is a Swiss biotechnology firm operating from Geneva. The company originated as a spin-off from the University of Geneva, concentrating on the development of solutions for Antiphospholipid Syndrome (APS). This autoimmune disease is characterized by the formation of blood clots, leading to thrombosis, and complications in pregnancy. The company aims to be a key partner for healthcare professionals by providing tools for the diagnosis and management of APS.

The company's primary focus is on creating diagnostic tests and therapies for APS. Endotelix is developing a rapid, lateral flow assay (LFA)-type diagnostic test to measure the levels of antiphospholipid antibodies (aPL), specifically anti-ß2GP1 IgG and IgM. This test is designed to be more sensitive and faster than existing assays. In a joint effort with the Geneva University Hospitals (HUG) and the University of Geneva (UNIGE), Endotelix has developed a new approach that significantly increases the detection likelihood of the syndrome from 40% to 85%, which could enable earlier screening. The company has also created an ELISA test for hospital and research use. Their business activities include operating laboratories, research centers, and the development and trade of medical and pharmaceutical products.

Endotelix's target clients include healthcare providers, hospitals, and research laboratories. The firm serves the medical diagnostics and biotechnology markets. The business model appears to be centered on the research, development, and commercialization of its diagnostic products and future therapies. Revenue generation will likely stem from the sale of these diagnostic tests to clinical and research facilities. Key milestones include receiving the UNIGE Spin-off award in 2018 and securing CHF 150,000 from the Venture Kick initiative in 2020. The company also completed a seed funding round in early 2024 and announced the full clinical validation of its technology in mid-2023. In March 2023, Endotelix raised $107K in a seed round from the investor Fongit.

Keywords: Antiphospholipid Syndrome, APS diagnostics, thrombosis test, pregnancy loss diagnostics, autoimmune disease testing, medical diagnostics, biotechnology, rapid diagnostic test, immunoassay, ELISA test, anti-ß2GP1 antibodies, diagnostic solutions, Geneva biotech, clinical validation, medical research, healthcare solutions, haemostasis, vascular biology, in-vitro diagnostics, serological testing